Therapeutic Targeting of Neuroendocrine Prostate Cancer
Abstract
Increased incidence of treatment induced neuroendocrine prostate cancer (NEPC) is particularly alarming as this diagnosis is associated with poor prognosis and decades of cytotoxic chemotherapy as the only treatment option. We previously identified neuronal transcription factor BRN2 as a potent driver of neuroendocrine differentiation and an attractive target in NEPC. Our goal is to Evaluate the mechanism by which BRN2 alters chromatin architecture to support neuroendocrine lineage reprogramming. We used unbiased approach to identify BRN2 cofactors using both in house and publicly available BRN2 ChIPseq and Rapid immunoprecipitation mass spectrometry. Our research demonstrates that BRN2 regulates chromatin organization/remodeling, pre-mRNA splicing, and cell cycle progression (especially at the G2-M checkpoint and during mitosis) through direct interactions with important factors involved in these processes and also through transcriptional regulation of the expression of such factors. Importantly, task that we were planning to achieved were setback because of the COVID restriction that were imposed by our Canadian government and the University of British Columbia. We applied and received an extension to complete our proposed tasks.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2021
- Accession Number
- AD1149969
Entities
People
- Amina Zoubeidi
Organizations
- University of British Columbia
- University of Washington